1. Home
  2. IGMS

IGMS

IGM Biosciences Inc.

Logo IGM Biosciences Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

Founded: N/A Country:
United States
United States
Employees: 224 City: MOUNTAIN VIEW
Market Cap: 423.3M IPO Year: 2019
Target Price: $17.25 AVG Volume (30 days): 261.5K
Analyst Decision: Buy Number of Analysts: 9
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -4.71 EPS Growth: N/A
52 Week Low/High: $3.81 - $17.70 Next Earning Date: 05-10-2024
Revenue: $2,130,000 Revenue Growth: 99.25%
Revenue Growth (this year): 45.4% Revenue Growth (next year): 250.95%

Share on Social Networks: